Litcius/Paper detail

Guillain-Barré syndrome after COVID-19 in Japan

Takehisa Hirayama, Yu Hongo, Kenichi Kaida, Osamu Kano

2020BMJ Case Reports38 citationsDOIOpen Access PDF

Abstract

We report the first case of Guillain-Barré syndrome (GBS) associated with SARS-CoV-2 infection in Japan. A 54-year-old woman developed neurological symptoms after SARS-CoV-2 infection. We tested for various antiganglioside antibodies, that had not been investigated in previous cases. The patient was diagnosed with GBS based on neurological and electrophysiological findings; no antiganglioside antibodies were detected. In previous reports, most patients with SARS-CoV-2-infection-related GBS had lower limb predominant symptoms, and antiganglioside antibody tests were negative. Our findings support the notion that non-immune abnormalities such as hyperinflammation following cytokine storms and microvascular disorders due to vascular endothelial damage may lead to neurological symptoms in patients with SARS-CoV-2 infection. Our case further highlights the need for careful diagnosis in suspected cases of GBS associated with SARS-CoV-2 infection.

Topics & Concepts

Guillain-Barre syndromeMedicineCytokine stormAntibodyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyImmune system2019-20 coronavirus outbreakCytokinePathologyDiseaseOutbreakInfectious disease (medical specialty)Peripheral Neuropathies and DisordersLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research